Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-25T04:09:51.596Z Has data issue: false hasContentIssue false
  • English
  • Français

Expression of Urotensin II During Focal Cerebral Ischemic in Diabetic Rats

Published online by Cambridge University Press:  20 October 2014

Lin Tian ,
Yunqian Li ,
Wei Hua ,
Ying Jia ,
Min Zhou ,
Yunhe Gu  and
Jiping Qi
Lin Tian
Affiliation:
Department of Pathology, the First Affiliated Hospital of Harbin Medical University, Harbin
Yunqian Li
Affiliation:
Department of Neurosurgery, the First Hospital, Jilin University, Changchun, PR China
Wei Hua
Affiliation:
Department of Pathology, the First Affiliated Hospital of Harbin Medical University, Harbin
Ying Jia
Affiliation:
Department of Pathology, the First Affiliated Hospital of Harbin Medical University, Harbin
Min Zhou
Affiliation:
Department of Pathology, the First Affiliated Hospital of Harbin Medical University, Harbin
Yunhe Gu
Affiliation:
Department of Pathology, the First Affiliated Hospital of Harbin Medical University, Harbin
Jiping Qi*
Affiliation:
Department of Pathology, the First Affiliated Hospital of Harbin Medical University, Harbin
*
Department of Pathology, the First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, PR China; Email: [email protected].
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The objective of this study was to explore the expression of urotensin II (UII), its receptor (GPR14), and vascular endothelial growth factor (VEGF), as well as their associations in the ischaemic brains of rats with focal cerebral ischaemia, under normal and diabetic conditions.

Methods:

Diabetes mellitus (DM) was induced by injection of streptozotocin (STZ) into Sprague—Dawley rats. Focal cerebral ischaemia was induced by middle cerebral artery occlusion (MCAO) four weeks after DM onset by STZ. Rats (n=80) were divided into four groups: normal control, DM, MCAO, and DM/MCAO. Immunohistochemistry and reverse-transcriptase-polymerase chain reaction (RT-PCR) were used to detect the expression of UII, GPR14 and VEGF in the diabetic and ischaemic brain.

Results:

Expression of UII and GPR14 was increased at mRNA and protein levels in the DM and MCAO group compared with controls. In the DM/MCAO group, expression of UII and GPR14 was increased significantly in the ischaemic brain, and was accompanied by a significantly increased VEGF expression.

Conclusion:

Diabetes mellitus was seen to aggravate brain lesions after ischaemia, and UII may have an important role.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 41 , Issue 4 , July 2014 , pp. 498 - 503
Copyright
Copyright © The Canadian Journal of Neurological 2014

References

1.Berlind, A.Teleost caudal neurosecretory system: release of urotensin II from isolated urophyses. Gen Comp Endocrinol. 1972;18(3):557–60.CrossRefGoogle ScholarPubMed
2.Ames, RS, Sarau, HM, Chambers, JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401(6750):282–6.CrossRefGoogle ScholarPubMed
3.Hirose, T, Takahashi, K, Mori, N, et al. Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1. Peptides. 2009;30(6):1124–9.CrossRefGoogle ScholarPubMed
4.Matsushita, M, Shichiri, M, Imai, T, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 2001;19(12):2185–90.CrossRefGoogle ScholarPubMed
5.Ong, KL, Wong, LY, Man, YB, et al. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides. 2006;27(7):1659–67.CrossRefGoogle ScholarPubMed
6.Sidharta, PN, Wagner, FD, Bohnemeier, H, et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther. 2006;80(3):246–56.CrossRefGoogle ScholarPubMed
7.Totsune, K, Takahashi, K, Arihara, Z, et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides. 2004;25(10):1809–14.CrossRefGoogle ScholarPubMed
8.Vogt, L, Chiurchiu, C, Chadha-Boreham, H, et al. Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. Hypertension. 2010;55(5):1206–9.CrossRefGoogle ScholarPubMed
9.Dai, HY, Guo, XG, Ge, ZM, et al. Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy. J Diabetes Complications. 2008;22(2):137–43.CrossRefGoogle ScholarPubMed
10.Dai, HY, Kang, WQ, Wang, X, et al. The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regul Pept. 2007;140(1–2):88–93.CrossRefGoogle ScholarPubMed
11.Langham, RG, Kelly, DJ, Gow, RM, et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis. 2004;44(5):826–31.CrossRefGoogle ScholarPubMed
12.Tzanidis, A, Hannan, RD, Thomas, WG, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res. 2003;93(3):246–53.CrossRefGoogle ScholarPubMed
13.Zhang, YG, Li, YG, Liu, BG, et al. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin. 2007;28(1):36–43.CrossRefGoogle ScholarPubMed
14.Davidson, EP, Coppey, LJ, Calcutt, NA, Oltman, CL, Yorek, MA.Diet-induced obesity in Sprague–Dawley rats causes microvascular and neural dysfunction. Diabetes Metab Res Rev. 2010;26(4):306–18.CrossRefGoogle ScholarPubMed
15.Mellbin, LG, Malmberg, K, Waldenström, A, Wedel, H, Rydén, L, DIGAMI 2 investigators. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial. Heart. 2009;95(9):721–7.CrossRefGoogle ScholarPubMed
16.Jorgensen, HS, Nakayama, H, Raaschou, HO, Olsen, TS.Effect of blood pressure and diabetes on stroke in progression. Lancet. 1994;344(8916):156–9.CrossRefGoogle ScholarPubMed
17.Bravata, DM, Kim, N, Concato, J, Brass, LM.Hyperglycaemia in patients with acute ischemic stroke: how often do we screen for undiagnosed diabetes? QJM. 2003;96(7):491–7.CrossRefGoogle Scholar
18.Williams, LS, Rotich, J, Qi, R, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology. 2002;59(1):67–71.CrossRefGoogle ScholarPubMed
19.Badr, AE, Yin, W, Mychaskiw, G, Zhang, JH.Dual effect of HBO on cerebral infarction in MCAO rats. Am J Physiol Regul Integr Comp Physiol. 2001;280(3):R766–70.CrossRefGoogle ScholarPubMed
20.Yin, D, Zhou, C, Kusaka, I, et al. Inhibition of apoptosis by hyperbaric oxygen in a rat focal cerebral ischemic model. J Cereb Blood Flow Metab. 2003;23(7):855–64.CrossRefGoogle Scholar
21.Bergeron, M, Yu, AY, Solway, KE, Semenza, GL, Sharp, FR.Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci. 1999;11(12):4159–70.CrossRefGoogle ScholarPubMed
22.Martini, SR, Kent, TA.Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab. 2007;27(3):435–51.CrossRefGoogle ScholarPubMed
23.Rossowski, WJ, Cheng, BJ, Taylor, JE, Datta, R, Coy, DH.Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinases; inhibition by somatostatin receptor antagonists. Eur J Pharmacol. 2002;438(3):159–70.CrossRefGoogle Scholar
24.Gao, S, Oh, YB, Park, BM, Park, WH, Kim, SH.Urotensin, IIprotects ischemic reperfusion injury of hearts through ROS and antioxidant pathway. Peptides. 2012;36(2):199–205.CrossRefGoogle ScholarPubMed
25.Lindsberg, PJ, Roine, RO.Hyperglycemia in acute stroke. Stroke. 2004;35(2):363–4.CrossRefGoogle ScholarPubMed
26.Capes, SE, Hunt, D, Malmberg, K, Pathak, P, Gerstein, HC.Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32(10):2426–32.CrossRefGoogle ScholarPubMed
27.Ogunshola, OO, Stewart, WB, Mihalcik, V, Solli, T, Madri, JA, Ment, LR.Neuronal VEGF expression correlates with angiogenesis in postnatal developing rat brain. Brain Res Dev Brain Res. 2000;119(1):139–53.CrossRefGoogle ScholarPubMed
28.Ma, Y, Qu, Y, Fei, Z.Vascular endothelial growth factor in cerebral ischemia. J Neurosci Res. 2011;89(7):969–78.CrossRefGoogle ScholarPubMed
29.Kanazawa, M, Igarashi, H, Kawamura, K, et al. Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment. J Cereb Blood Flow Metab. 2011;31(6):1461–74.CrossRefGoogle ScholarPubMed
30.Yamamizu, K, Yamashita, JK.Roles of cyclic adenosine monophos phate signaling in endothelial cell differentiation and arterial-venous specification during vascular development. Circ J. 2011;75 (2):253–60.CrossRefGoogle Scholar
31.Jin, X, Ge, X, Zhu, DL, et al. Expression and function of vascular endothelial growth factor receptors (Flt-1 and Flk-1) in vascular adventitial fibroblasts. J Mol Cell Cardiol. 2007;43(3):292–300.CrossRefGoogle ScholarPubMed
32.Pan, P, Fu, H, Zhang, L, et al. Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol. 2010;11:36.CrossRefGoogle ScholarPubMed
33.Lacza, Z, W Busija, D., Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci. 2006;78(23):2763–6.CrossRefGoogle ScholarPubMed
34.Iglewski, M, Grant, SR.Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells. Vasc Health Risk Manag. 2010;6:723–34.CrossRefGoogle ScholarPubMed
35.Zhang, YG, Li, J, Li, YG, Wei, RH.Urotensin II induces phenotypic differentiation, migration and collagen synthesis of adventitial fibro-blasts from rat aorta. J Hypertens. 2008;26(6):1119–26.CrossRefGoogle Scholar
36.Song, N, Ding, W, Chu, S, et al. Urotensin II stimulates vascular endothelial growth factor secretion from adventitial fibroblasts in synergy with angiotensin II. Circ J. 2012;76(5):1267–73.CrossRefGoogle ScholarPubMed
37.Sartore, S, Chiavegato, A, Faffin, E, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: From innocent bystander to active participant. Cir Res. 2011;89(12): 1111–21.CrossRefGoogle Scholar
38.Chuquet, J, Lecrux, C, Chatenet, D, et al. Effects of urotensin-II on cerebral blood flow and ischemia in anesthetized rats. Exp Neurol. 2008;210(2):577–84.CrossRefGoogle ScholarPubMed